Drug Pipeline

Drug Pipeline Market Research Reports

1 . Drug Pipeline Market Research Reports Analysis and Trends

Discovering and bringing new drugs to mainstream commercial market typically takes an average of 10-15 years of research and clinical development efforts. Drug developers need to make sure safe and effective drug available for patient in quick time. The first step is to target the protein available in the patient’s body that is associated with microorganism causing a disease, through tracking of cellular network of proteins an appropriate target for a drug is selected. Through a series of trials, right drug candidate got chosen.
 
According to “NOVARTIS”, bringing a new drug in market takes 14 years of research and cost around USD 2 billion, 10K+ clinical trials out of these, one leads to successful drug development.
Titlesort descending Published Pages Price
Acute Liver Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 46 USD 2,000.00
Acute Lung Injury (Respiratory) - Drugs in Development, 2021 Apr 30 2021 115 USD 2,000.00
Acute Lung Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 80 USD 2,000.00
Acute Lymphoblastic Lymphoma (Oncology) - Drugs in Development, 2021 Apr 30 2021 45 USD 2,000.00
Acute Lymphoblastic Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 45 USD 2,000.00
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) - Drugs in Development, 2021 Oct 31 2021 2145 USD 2,500.00
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2018 May 29 2018 925 USD 2,000.00
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2020 May 30 2020 1536 USD 2,500.00
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2019 Dec 16 2019 1463 USD 2,500.00
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Oct 31 2022 820 USD 2,000.00
Acute Lymphocytic Leukemia - Pipeline Review, H2 2020 Nov 30 2020 1809 USD 2,500.00
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) (Oncology) - Drugs in Development, 2021 Dec 30 2021 4011 USD 2,500.00
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2018 Jun 29 2018 2103 USD 2,500.00
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2020 Jun 30 2020 3103 USD 2,500.00
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2019 Dec 16 2019 2792 USD 2,500.00
Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Dec 28 2022 1560 USD 2,500.00
Acute Opioid Overdosage (Toxicology) - Drugs in Development, 2021 Apr 30 2021 40 USD 2,000.00
Acute Opioid Overdosage Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 43 USD 2,000.00
Acute Promyelocytic Leukemia (Oncology) - Drugs in Development, 2021 Apr 30 2021 35 USD 2,000.00
Acute Promyelocytic Leukemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 40 USD 2,000.00
Acute Renal Failure (ARF) (Acute Kidney Injury) (Genitourinary Disorders) - Drugs in Development, 2021 Mar 31 2021 242 USD 2,500.00
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019 Apr 29 2019 149 USD 2,500.00
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020 Jan 14 2020 197 USD 2,000.00
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2018 Jul 17 2018 130 USD 2,000.00
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2019 Nov 29 2019 204 USD 2,000.00
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H2 2020 Jul 31 2020 218 USD 2,000.00
Acute Renal Failure (ARF) (Acute Kidney Injury) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Mar 31 2022 213 USD 2,000.00
Acute Respiratory Distress Syndrome (Respiratory) - Drugs in Development, 2021 Mar 31 2021 836 USD 2,500.00
Acute Respiratory Distress Syndrome - Pipeline Review, H1 2019 Feb 1 2019 111 USD 2,000.00
Acute Respiratory Distress Syndrome - Pipeline Review, H1 2020 Jan 31 2020 129 USD 2,000.00
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2018 Jul 17 2018 107 USD 2,000.00
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2019 Nov 11 2019 123 USD 2,000.00
Acute Respiratory Distress Syndrome - Pipeline Review, H2 2020 Jul 31 2020 667 USD 2,000.00
Acute Respiratory Distress Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Mar 31 2022 197 USD 2,000.00
Acute Respiratory Failure (Respiratory) - Drugs in Development, 2021 Apr 30 2021 30 USD 2,000.00
Acute Respiratory Failure Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 35 USD 2,000.00
Acute Sensorineural Hearing Loss (Ear Nose Throat Disorders) - Drugs in Development, 2021 Apr 30 2021 45 USD 2,000.00
Acute Sensorineural Hearing Loss Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 47 USD 2,000.00
Acute Spinal Cord Injury (Central Nervous System) - Drugs in Development, 2021 Apr 30 2021 35 USD 2,000.00
Acute Spinal Cord Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 42 USD 2,000.00
Acyl CoA Desaturase (Fatty Acid Desaturase or Delta 9 Desaturase or Stearoyl CoA Desaturase or SCD or EC 1.14.19.1) - Pipeline Review, H1 2018 May 29 2018 42 USD 3,500.00
Acyl CoA Desaturase - Pipeline Review, H1 2020 Jan 14 2020 51 USD 3,500.00
Acyl CoA Desaturase - Pipeline Review, H2 2019 Dec 27 2019 51 USD 3,500.00
Acyl CoA Desaturase - Pipeline Review, H2 2020 Jul 31 2020 53 USD 3,500.00
Addiction (Central Nervous System) - Drugs in Development, 2021 Apr 30 2021 45 USD 2,000.00
Addiction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 295 USD 2,500.00
Adenocarcinoma (Oncology) - Drugs in Development, 2021 Apr 30 2021 100 USD 2,000.00
Adenocarcinoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 116 USD 2,000.00
Adenocarcinoma Of The Gastroesophageal Junction (Oncology) - Drugs in Development, 2021 Apr 30 2021 260 USD 2,500.00
Adenocarcinoma Of The Gastroesophageal Junction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players May 2 2022 250 USD 2,500.00

Clients Who Trust Us

Market Research Reports Inc. Customers

Need tailor made market research solution? We can help you with that too.

About Us

At Market Research Reports, Inc. we aim to make it easier for decision makers to find relevant information and locate right market research reports which can save their time and assist in what they do best, i.e. take time-critical decisions.

We work with our associate Global market research firms who are known leaders in their respective domains to obtain right market research solution for our customer’s needs, be it custom research or syndicated research reports.

Contact Us

Market Research Reports, Inc
16192 Coastal Hwy
Lewes
, DE 19958, USA

USA: +1-302-703-9904

India: +91-8762746600

marketresearchreports

info@marketresearchreports.com

User login

Stay Connected